Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
Total Valuation
Abeona Therapeutics has a market cap or net worth of $224.48M. The enterprise value is $179.23M.
Market Cap$224.48M
Enterprise Value$179.23M
Share Statistics
Abeona Therapeutics has 48.80M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding48.80M
Owned by Insiders7.46%
Owned by Instutions50.61%
Financial Efficiency
Abeona Therapeutics’s return on equity (ROE) is -1.45 and return on invested capital (ROIC) is -64.80%.
Return on Equity (ROE)-144.75%
Return on Assets (ROA)-58.51%
Return on Invested Capital (ROIC)-64.80%
Return on Capital Employed (ROCE)-69.53%
Revenue Per Employee$0
Profits Per Employee-$468,632.353
Employee Count136
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Abeona Therapeutics is -3.59. Abeona Therapeutics’s PEG ratio is 0.09.
PE Ratio-3.59
PS Ratio0.00
PB Ratio5.19
Price to Fair Value5.19
Price to FCF-3.91
Price to Operating Cash Flow-4.08
PEG Ratio0.09
Income Statement
In the last 12 months, Abeona Therapeutics had revenue of $0.00 and earned -$63.73M in profits. Earnings per share was -$1.83.
Revenue$0.00
Gross Profit-$2.39M
Operating Income-$64.21M
Pretax Income-$63.73M
Net Income-$63.73M
EBITDA-55.64M
Earnings Per Share (EPS)-1.83
Cash Flow
In the last 12 months, operating cash flow was -$56.02M and capital expenditures -$2.45M, giving a free cash flow of -$58.46M billion.
Operating Cash Flow-$56.02M
Free Cash Flow-$58.46M
Free Cash Flow per Share-$1.20
Dividends & Yields
Abeona Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-25.57%
Earnings Yield-27.88%
Stock Price Statistics
Beta0.55
52-Week Price Change-36.60%
50-Day Moving Average5.23
200-Day Moving Average5.54
Relative Strength Index (RSI)51.13
Average Volume (3m)625.92K
Important Dates
Abeona Therapeutics upcoming earnings date is May 8, 2025, TBA.
Last Earnings DateMar 20, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Abeona Therapeutics as a current ratio of 6.08, with Debt / Equity ratio of 0.52
Current Ratio6.08
Quick Ratio6.08
Debt to Market Cap0.10
Net Debt to EBITDA<0.01
Interest Coverage Ratio15.26
Taxes
In the past 12 months, Abeona Therapeutics has paid $680.72K in taxes.
Income Tax$680.72K
Effective Tax Rate0.00%
Enterprise Valuation
Abeona Therapeutics EV to EBITDA ratio is -3.56, with an EV/FCF ratio of -3.91.
EV to Sales0.00
EV to EBITDA-3.56
EV to Free Cash Flow-3.91
EV to Operating Cash Flow-4.08
Balance Sheet
Abeona Therapeutics has $97.72M in cash and marketable securities with $23.05M in debt, giving a net cash position of -$74.67M billion.
Cash & Marketable Securities$97.72M
Total Debt$23.05M
Net Cash-$74.67M
Net Cash Per Share-$1.53
Tangible Book Value Per Share$1.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Abeona Therapeutics is $17.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$17.50
Price Target Upside255.69%
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-100.00%
EPS Growth Forecast30.33%